SMARCA2 and cancer: Leveraging the privileged VH101-phenol as VHL ligase recruiting moiety, the phenolic linkage has been exploited in the structure-guided design of degraders targeting the BAF ATPase subunits SMARCA2 and SMARCA4 as potential therapeutics for BAF ATPase dependent cancer.113 Capitalising on the cocrystal structure of the initial prototype degrader 89 binding to VCB and SMARCA2BD, attractive regions for degrader optimisation were identified.